Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCESIVE
2022-502778-18-00Phase 3Completed
- Sponsor
- Polpharma Biologics
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in autoimmune colitis (2 arms), sponsored by Polpharma Biologics. Primary endpoint: Clinical response rate at Week 6. Started Jun 2023; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-502778-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502778-18-00.